Roche's fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
New Phase II data show vast majority of patients experiencing no relapses or disability progression Fenebrutinib suppressed acute and chronic MRI lesions Fenebrutinib's safety profile was consistent with previous and ongoing clinical trials across multiple diseases including more than 2,700 people to date Basel, 04 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new 48-week data for the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib from the Phase II FENopta open-labe ...